AndroGel Heart Attack Risk
Doctor Testifies about AndroGel’s Heart Attack Risks
July 14, 2017
Northwestern University cardiologist Dr. Hossein Ardehali testified in a Chicago federal courtroom that there is enough evidence to suggest a link between testosterone replacement therapy drugs and an increased heart attack risk.
Dr. Ardehali testified as an expert witness on behalf of plaintiff Jesse Mitchell, who alleges that AndroGel, a topical testosterone replacement therapy drug manufactured by AbbVie, caused the heart attack that he suffered in 2012. Also central to Mitchell’s case are his allegations that AbbVie did not test the drug satisfactorily, and that it encouraged its use in men for whom testosterone replacement was not medically appropriate.
Mitchell’s case is the first of more than 4000 cases filed against AbbVie over AndroGel in a Multi-District Litigation (MDL) legal action.
Dr. Ardehali, in his testimony, likened the hazardous side effects of AndroGel in men to those suffered by women who had undergone estrogen therapy. Estrogen therapy has been implicated in increased risks of stroke, breast cancer, and heart disease.
The trial is ongoing in Chicago.
If you have suffered health problems as a result of dangerous or misprescribed drugs, the attorneys at TheLawFirm.com want to hear from you. Contact us for your free consultation.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!